Compare · CTKB vs RVTY
CTKB vs RVTY
Side-by-side comparison of Cytek Biosciences Inc. (CTKB) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CTKB and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $11.12B, about 21.7x CTKB ($511.4M).
- Over the past year, CTKB is up 20.4% and RVTY is up 3.4% - CTKB leads by 17.0 points.
- CTKB has been more active in the news (12 items in the past 4 weeks vs 2 for RVTY).
- RVTY has more recent analyst coverage (19 ratings vs 13 for CTKB).
PerformanceCTKB+20.36%RVTY+3.41%
2025-06-16+0.00%2026-06-12
- Company
- Cytek Biosciences Inc.
- Revvity Inc.
- Price
- $3.96-1.25%
- $99.66-1.73%
- Market cap
- $511.4M
- $11.12B
- 1M return
- +7.90%
- +4.87%
- 1Y return
- +20.36%
- +3.41%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 12
- 2
- Recent ratings
- 13
- 19
Latest CTKB
- Director Ball Jack converted options into 43,973 shares, increasing direct ownership by 103% to 86,678 units (SEC Form 4)
- SEC Form 4 filed by Director Muir Glenn P
- SEC Form 3 filed by new insider Muir Glenn P
- SEC Form 4 filed by Director Chin Richard
- Director Imper Vera converted options into 43,973 shares, increasing direct ownership by 280% to 59,679 units (SEC Form 4)
- Director Neff Deborah J converted options into 43,973 shares, increasing direct ownership by 280% to 59,679 units (SEC Form 4)
- Director Holder Michael converted options into 43,973 shares, increasing direct ownership by 263% to 60,694 units (SEC Form 4)
- Cytek Biosciences to participate at the Singular Research's Las Vegas Invitational Conference
- Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
- Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
Latest RVTY
- Wolfe Research resumed coverage on Revvity
- SEC Form SD filed by Revvity Inc.
- SEC Form 10-Q filed by Revvity Inc.
- Director Klobuchar Michael A was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Vandebroek Sophie V. was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Michas Alexis P was granted 2,684 shares, increasing direct ownership by 4% to 63,767 units (SEC Form 4)
- Director Witney Frank was granted 2,280 shares, increasing direct ownership by 11% to 23,354 units (SEC Form 4)
- Director Witz Pascale was granted 2,280 shares, increasing direct ownership by 17% to 15,985 units (SEC Form 4)
- Director Barrett Peter was granted 2,280 shares, increasing direct ownership by 9% to 28,293 units (SEC Form 4)
- Director Mcmurry-Heath Michelle was granted 2,280 shares, increasing direct ownership by 54% to 6,513 units (SEC Form 4)